Research Article
Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
Table 3
Chemotherapy regimens received after molecular profiling.
| | Treatment | Number | Frequency % |
| | Combination therapy | | | | FOLFIRI/XELIRI | 16 | 34.0 | | GEMOX | 3 | 6.4 | | FOLFOX/XELOX | 2 | 4.3 | | FOLFIRI + cetuximab | 2 | 4.3 | | Capecitabine + cisplatin | 1 | 2.1 | | 5-FU + mitomycin | 1 | 2.1 | | 5-FU + adriamycin + methotrexate | 1 | 2.1 | | Gemcitabine + nab-paclitaxel | 1 | 2.1 | | Gemcitabine + paclitaxel | 1 | 2.1 | | Oxaliplatin + bevacizumab | 1 | 2.1 | | Pegylated liposomal doxorubicin + cetuximab | 1 | 2.1 |
| | Monotherapy | | | | 5-FU/capecitabine | 5 | 10.6 | | Nab-paclitaxel | 5 | 10.6 | | Sunitinib | 1 | 2.1 | | Cetuximab | 1 | 2.1 | | Gemcitabine | 1 | 2.1 | | Sorafenib | 1 | 2.1 | | Temozolomide | 1 | 2.1 | | Mitomycin | 1 | 2.1 | | Everolimus | 1 | 2.1 |
| | Total of regimens received | 47 | 100 |
|
|
5-FU: 5-fluorouracil; FOLFIRI: 5-fluorouracil/irinotecan; FOLFOX: 5-fluorouracil/oxaliplatin; GEMOX: gemcitabine/oxaliplatin; XELIRI: capecitabine/irinotecan; XELOX: capecitabine/oxaliplatin.
|
